PainReform Overview
PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Its proprietary drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while also reducing the use of opiates commonly administered after surgery. The companys strategy is to incorporate generic drugs which have been proven safe and effective with its proprietary extended-release drug-delivery system in order to create a major improvement in therapy via extended-release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (FDA). The 505(b)(2) new drug application process provides for FDA approval of a new drug based in part on data developed by others, including references in published literature and data previously reviewed by the FDA in its approval of a separate application. This pathway can significantly reduce future time and costs associated with clinical development. PainReforms first product, PRF-110, is based on the local anesthetic ropivacaine and is designed to target the post-operative pain relief market.
Cumulative Funding Raised Over Time ($)
$12.0MDec 2017
$13.3MDec 2023
$19.3MMar 2021
Latest News
growth-positive
PainReform Provides Business Update for the Six Months Ended June 30, 2025
PainReform Ltd, a specialty pharmaceutical company, provided a business update for the first half of 2025, highlighting its dual strategy in pharmaceuticals and renewable energy. The company completed a majority investment in LayerBio, acquiring the OcuRing™-K platform, a breakthrough cataract therapy. It also advanced its PRF-110 product with ongoing R&D. In renewable energy, PainReforms DeepSolar division completed a 92MW pilot project with Econergy, transitioning into its first commercial agreement. The company reduced its net loss and maintained a positive working capital, emphasizing financial discipline and resource efficiency. PainReform is focused on expanding its portfolio of non-opioid solutions and scaling its renewable energy platform.
AcquisitionProduct StageCustomersPartners
growth-positive
BC-Most Active Stocks
The article provides a list of the most active stocks on the Nasdaq, NYSE, and NYSE American exchanges, highlighting their trading volumes, high and low prices, last trading price, and price changes. Among the companies listed, Gaxos.ai Inc. showed a significant positive change in its stock price, indicating a growth-positive impact. The article focuses on stock performance and trading activity, providing insights into the market dynamics of various companies. No specific details about partnerships, acquisitions, or other business activities are mentioned.
growth-positive
PainReform/DeepSolar Accepted into NVIDIA Connect Program
PainReform Ltds solar energy business unit, DeepSolar, has been accepted into the NVIDIA Connect Program, which provides access to advanced AI frameworks and tools. This collaboration aims to enhance DeepSolar Predict, an AI-driven solar forecasting platform, to improve weather prediction accuracy by up to 50%. This advancement is crucial for solar asset owners to optimize energy asset performance, reduce imbalance penalties, and maximize revenue. The partnership with NVIDIA is expected to position PainReform as a leader in performance-driven solar asset management. Initial engagements with PV developers and utility-scale operators are underway to evaluate the platform in real-world settings.
Partners
growth-positive
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd, a pharmaceutical company, has acquired a majority equity interest in LayerBio, Inc., a biotechnology firm specializing in sustained-release drug delivery technologies for ophthalmology. This acquisition focuses on LayerBios OcuRing™-K technology, which offers a dropless solution for pain and inflammation control following cataract surgery. The acquisition positions PainReform to address the growing demand in the cataract surgery market, particularly in the U.S., where the market is valued at over $3 billion. OcuRing™-K is a bioerodible implant designed to deliver a controlled, localized release of Ketoralac, eliminating the need for daily eye drops and improving patient compliance. This move is expected to significantly benefit PainReform by tapping into the expanding market driven by aging populations and increasing surgical procedures.
AcquisitionProduct StageCustomers
growth-positive
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio
PainReform Ltd has announced a strategic investment agreement with LayerBio Inc., a biotechnology company specializing in long-acting, non-opiate treatments for ophthalmic surgery. This investment aims to expand PainReforms non-opiate pain management pipeline into the ophthalmology sector, particularly targeting the cataract surgery market. PainReform will acquire a majority equity stake in LayerBio and a majority position on its board, with an investment totaling $3 million. The funds will support a Phase II clinical trial of LayerBios OcuRing-K, a sustained-release intraocular ring for post-cataract surgery treatment. The transaction is expected to close by the end of July 2025.
InvestmentPartnersProduct Stage
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $46.3M |
| Last funding | $4M |
| Stage | Public |
| Rounds | 5 |
| Investors | 4 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | painreform.com |
Locations
Yigal Alon St 65, Tel Aviv-Yafo, Israel
Photos & Videos
No files yet
PainReform Business
Business models
B2B2C, B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsProvidersCore Technology
BiologicalsTags (8)
pharmaceuticalspain-reliefgeneric-drugsdrug-deliverypatientslife-sciencestreatmentstherapeuticsGeographic Markets
EuropeNorth AmericaUnited StatesIsraelAsiaPainReform Financials
$46.3M
Total funding
Undisclosed
Capital raised
$4M
Last funding
Public
Funding stage
5
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$12.0MDec 2017
$13.3MDec 2023
$19.3MMar 2021
Private Equity Funding
PIPE
Dec 2023
$1.3M
Undisclosed Investor(s)
PIPE
Mar 2021
$6M
Undisclosed Investor(s)
Undisclosed Round
Dec 2017
$12M
XT Venture Capital, V Partners, Medica Venture Partners
Public Offering / Exit
POEvent
Apr 2024
Undisclosed
POEvent
Sep 2020
Undisclosed
Mergers & Acquisitions
MNAEvent
Aug 2025
Undisclosed
PainReform Lifecycle
Cumulative Funding Raised Over Time
$12.0MDec 2017
$13.3MDec 2023
$19.3MMar 2021
All Events
PIPE
Dec 2023
$1.3M
Undisclosed Investor(s)
PIPE
Mar 2021
$6M
Undisclosed Investor(s)
Undisclosed Round
Dec 2017
$12M
XT Venture Capital, V Partners, Medica Venture Partners
POEvent
Apr 2024
Undisclosed
POEvent
Sep 2020
Undisclosed
MNAEvent
Aug 2025
Undisclosed
PainReform News
89 articles
growth-positive
PainReform Provides Business Update for the Six Months Ended June 30, 2025
PainReform Ltd, a specialty pharmaceutical company, provided a business update for the first half of 2025, highlighting its dual strategy in pharmaceuticals and renewable energy. The company completed a majority investment in LayerBio, acquiring the OcuRing™-K platform, a breakthrough cataract therapy. It also advanced its PRF-110 product with ongoing R&D. In renewable energy, PainReforms DeepSolar division completed a 92MW pilot project with Econergy, transitioning into its first commercial agreement. The company reduced its net loss and maintained a positive working capital, emphasizing financial discipline and resource efficiency. PainReform is focused on expanding its portfolio of non-opioid solutions and scaling its renewable energy platform.
AcquisitionProduct StageCustomersPartners
growth-positive
BC-Most Active Stocks
The article provides a list of the most active stocks on the Nasdaq, NYSE, and NYSE American exchanges, highlighting their trading volumes, high and low prices, last trading price, and price changes. Among the companies listed, Gaxos.ai Inc. showed a significant positive change in its stock price, indicating a growth-positive impact. The article focuses on stock performance and trading activity, providing insights into the market dynamics of various companies. No specific details about partnerships, acquisitions, or other business activities are mentioned.
growth-positive
PainReform/DeepSolar Accepted into NVIDIA Connect Program
PainReform Ltds solar energy business unit, DeepSolar, has been accepted into the NVIDIA Connect Program, which provides access to advanced AI frameworks and tools. This collaboration aims to enhance DeepSolar Predict, an AI-driven solar forecasting platform, to improve weather prediction accuracy by up to 50%. This advancement is crucial for solar asset owners to optimize energy asset performance, reduce imbalance penalties, and maximize revenue. The partnership with NVIDIA is expected to position PainReform as a leader in performance-driven solar asset management. Initial engagements with PV developers and utility-scale operators are underway to evaluate the platform in real-world settings.
Partners
growth-positive
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd, a pharmaceutical company, has acquired a majority equity interest in LayerBio, Inc., a biotechnology firm specializing in sustained-release drug delivery technologies for ophthalmology. This acquisition focuses on LayerBios OcuRing™-K technology, which offers a dropless solution for pain and inflammation control following cataract surgery. The acquisition positions PainReform to address the growing demand in the cataract surgery market, particularly in the U.S., where the market is valued at over $3 billion. OcuRing™-K is a bioerodible implant designed to deliver a controlled, localized release of Ketoralac, eliminating the need for daily eye drops and improving patient compliance. This move is expected to significantly benefit PainReform by tapping into the expanding market driven by aging populations and increasing surgical procedures.
AcquisitionProduct StageCustomers
growth-positive
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio
PainReform Ltd has announced a strategic investment agreement with LayerBio Inc., a biotechnology company specializing in long-acting, non-opiate treatments for ophthalmic surgery. This investment aims to expand PainReforms non-opiate pain management pipeline into the ophthalmology sector, particularly targeting the cataract surgery market. PainReform will acquire a majority equity stake in LayerBio and a majority position on its board, with an investment totaling $3 million. The funds will support a Phase II clinical trial of LayerBios OcuRing-K, a sustained-release intraocular ring for post-cataract surgery treatment. The transaction is expected to close by the end of July 2025.
InvestmentPartnersProduct Stage
growth-positive
Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
Blade Ranger Ltd., listed on the Tel Aviv Stock Exchange, announced the achievement of a milestone in its transaction with PainReform. The company sold its DeepSolar operations to PainReform in March 2025, receiving securities including common shares and warrants. Upon reaching the first milestone, Blade Ranger received 685,004 warrants exercisable at $0.01 per share, with PainReform shares trading at $1.91. This development enhances Blade Rangers financial flexibility, supporting its business development. The market value of the matured warrants is approximately NIS 4.5 million.
Acquired-by
growth-positive
PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar Projects
PainReform Ltd has launched a strategic pilot program with Econergy Renewable Energy Ltd to utilize its AI-powered DeepSolar™ platform at Econergys 92-megawatt photovoltaic plant in Romania. This pilot aims to enhance operational efficiency and energy yield at utility-scale solar facilities. The collaboration marks the first phase of a broader partnership, with plans to expand DeepSolars application across Econergys portfolio, potentially reaching 1 Gigawatt. The initiative reflects PainReforms commitment to using advanced technologies for improvements in clean energy operations and is expected to support the companys expansion into broader European and U.S. photovoltaic markets.
Product StagePartners
growth-positive
PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization Market
PainReform Ltd, a clinical-stage pharmaceutical company, has announced its expansion into the Smart Energy Management (SEM) sector through the acquisition of DeepSolar. This strategic move is part of PainReforms diversification strategy to tap into high-growth, tech-enabled markets. DeepSolar provides AI-driven software solutions for optimizing solar energy usage, which aligns with global trends towards decentralized and sustainable energy solutions. The acquisition allows PainReform to leverage its AI expertise in new verticals, enhancing its innovation footprint beyond pharmaceuticals. This expansion is expected to drive economic and environmental value, positioning PainReform at the forefront of intelligent energy optimization.
AcquisitionProduct Stage
growth-positive
PainReform Provides Year-End Business Update
PainReform Ltd, a specialty pharmaceutical company, has provided a business update for the year ending December 31, 2024. The company is advancing the clinical development of PRF-110, targeting post-operative pain relief, despite a temporary setback in its Phase 3 clinical trial. PainReform has acquired DeepSolar, an AI-driven solar analytics platform, marking its expansion into the clean energy sector. This acquisition is expected to drive revenue growth and enhance shareholder value. The company raised $0.9 million through its ATM program, helping it comply with Nasdaqs minimum shareholders’ equity requirement. Financial results show increased R&D expenses, primarily due to clinical trial costs.
AcquisitionInvestmentProduct Stage
growth-positive
PainReform completes acquisition of DeepSolar
PainReform has completed the acquisition of DeepSolar, an AI-driven solar analytics platform, from BladeRanger. This acquisition aims to expand DeepSolars customer base and increase market penetration among utility-scale solar operators, independent power producers, and residential users. DeepSolars SaaS model is expected to generate recurring revenue and reduce operational costs for customers through AI-driven automation. The acquisition includes all rights and assets associated with DeepSolar, and the core team from DeepSolar will join PainReform. BladeRanger received shares and warrants as part of the transaction. PainReform plans to explore strategic partnerships with utility companies and solar technology providers to drive further growth.
AcquisitionPartnersCustomers
growth-positive
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has successfully acquired DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd. This acquisition marks PainReforms strategic entry into the high-growth clean energy sector, leveraging DeepSolars AI solutions to optimize solar energy management. The acquisition aims to broaden DeepSolars customer base, targeting utility-scale solar operators and residential users. DeepSolars platform enhances energy production and reduces operational inefficiencies, offering a SaaS model for recurring revenue. The acquisition positions PainReform as a potential leader in solar asset optimization, while continuing its focus on pharmaceutical innovation.
Acquisition
growth-positive
Deepsolar is an advanced and innovative software platform for managing photovoltaic solar energy fields, which was acquired by Bladeranger at the start of 2023.
Bladeranger, a company specializing in drone-based solar panel cleaning technology, has sold its Deepsolar software to Painreform for approximately $4 million. This strategic move allows Bladeranger to focus on its core expertise while still benefiting from Deepsolars activities. The deal involves an exchange of shares and convertible stock warrants, with Bladeranger receiving Painreform shares representing about 9.9% of Painreforms existing shares. Painreform plans to invest in the further development and commercialization of Deepsolar, employing some of Bladerangers staff. Bladeranger anticipates a capital gain from this transaction by the first half of 2025.
Acquisition
growth-positive
Deepsolar, acquired by Bladeranger in early 2023, is a sophisticated software solution designed to optimize the management of photovoltaic solar energy fields.
Bladeranger, a company known for its drone-based solar panel cleaning technology, has sold its Deepsolar software to Painreform in a deal valued at approximately $4 million. This strategic move allows Bladeranger to focus on its core expertise while still benefiting from Deepsolars activities. The transaction involves an exchange of shares and convertible stock warrants, with Bladeranger receiving Painreform shares representing about 9.9% of Painreforms existing shares. Painreform plans to invest in further development and commercialization of Deepsolar, employing some of Bladerangers employees. This deal is expected to result in a capital gain for Bladeranger by the first half of 2025.
AcquisitionAcquired-byPartners
growth-positive
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced a strategic acquisition of DeepSolar, an AI-driven solar analytics platform owned by BladeRanger Ltd. This acquisition is expected to enhance PainReforms growth potential by integrating DeepSolars cutting-edge AI technology, which optimizes solar energy assets efficiency and profitability. DeepSolar serves both B2B and B2C sectors, providing solutions for large-scale solar operators and residential applications. The acquisition is set to close by the end of February 2025, subject to customary conditions. PainReform remains committed to advancing its drug delivery technologies while expanding its market reach through this acquisition.
AcquisitionCustomersPartners
growth-negative
PainReform Faces Setback in Phase 3 Trial for PRF-110
PainReform, a clinical-stage pharmaceutical company, announced that its Phase 3 clinical trial for PRF-110 did not meet its primary endpoint of providing effective postoperative pain relief over 72 hours. The data from the final 24-hour period could not be clarified, marking a setback for the company. Despite this, PainReform is continuing its research and development efforts to refine the drugs pharmacokinetics and pharmacodynamics, aiming to support future trials. PRF-110 is designed to provide extended postoperative analgesia, reducing the need for repeated doses and minimizing opiate use. The companys stock has seen a significant decline in year-to-date price performance, with a current market cap of $2.89 million.
growth-negative
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced an update on its Phase 3 clinical trial for PRF-110, a post-surgical pain management drug. While initial results showed significant pain reduction over placebo in the first 48 hours post-surgery, the data for the final 24 hours of the 72-hour study was inconclusive. As a result, the trial did not meet its primary endpoint. Despite this setback, PainReform is focusing on R&D to refine the drugs pharmacokinetics and pharmacodynamics, aiming to resolve the issue for future trials. The company is also reviewing strategic options, though no specific transactions are assured.
growth-positive
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced partial topline data from its Phase 3 clinical trial of PRF-110, a proprietary extended-release formulation of ropivacaine for post-surgical pain management. The initial analysis indicates that PRF-110 significantly reduces pain in the first 48 hours post-surgery, demonstrating its potential as an effective pain relief solution. However, data for the subsequent 24-hour period is unclear due to incoherence, and PainReform is working with Lotus Clinical Research to resolve this issue. The trial involves 428 patients and aims to evaluate the analgesic efficacy and safety of PRF-110 compared to placebo and plain ropivacaine. If successful, PainReform plans to initiate a second trial for hernia repair pain treatment.
growth-negative
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has received a notification from Nasdaq indicating that it no longer meets the minimum stockholders equity requirement for continued listing. The company has 45 days to submit a compliance plan, with a potential extension until May 3, 2025, if accepted. This notification does not immediately affect the trading of PainReforms shares on Nasdaq. PainReform is focused on reformulating established therapeutics, with its lead product PRF-110 targeting postoperative pain relief. The company faces challenges such as the need to raise additional capital, reliance on third parties for clinical trials, and compliance with regulatory requirements. The announcement highlights the risks and uncertainties affecting the company, including the political situation in Israel.
growth-negative
PainReform cut to Hold at Maxim amid ‘changed’ market dynamics
PainReform has been downgraded by Maxim analyst Naz Rahman from Buy to Hold due to changing market dynamics. The company is developing PRF-110 for post-operative pain treatment but faces challenges due to the approval of a generic version of Exparel, the market leader, in July 2024. This development affects PainReforms market opportunities and operational strategies. The company is progressing with its Phase 3 bunionectomy study, expected to complete in Q4, but still requires additional studies and capital to advance. PainReform has announced a significant share offering and plans a shareholder meeting for key votes. The company has filed a $50 million mixed securities shelf.
Investment
growth-positive
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced positive compatibility results for its lead product, PRF-110, in human clinical trials. The studies confirmed that PRF-110 does not affect the mechanical properties of common surgical sutures, PROLENE™ and Vicryl™, suggesting its safety and efficacy in post-surgical pain management. This milestone supports the companys goal of commercializing PRF-110, which offers extended, non-opiate pain relief. The announcement underscores the products potential to improve post-surgical care without compromising suture integrity.
growth-positive
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced the immediate exercise of certain outstanding warrants to purchase up to 989,300 ordinary shares at a reduced exercise price of $1.60 per share. The gross proceeds from this exercise are expected to be approximately $1.58 million. In consideration, the company will issue new unregistered warrants to purchase up to 1,978,600 ordinary shares. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The proceeds will be used for general corporate purposes. The event is expected to close on or about September 11, 2024.
Investment
growth-negative
Top Midday Decliners
MT Newswires reported on the top midday decliners on September 10, 2024. The article is accessible only to subscribers with a Silver or Gold subscription plan. The company encourages readers to upgrade their subscriptions to access premium news articles.
growth-positive
Upcoming Stock Splits This Week (September 9 to September 13) – Stay Invested
Tetra Tech, a consulting and engineering solutions provider, announced a five-for-one stock split approved by its board on July 29. The split aims to improve the stocks liquidity and make it more accessible to investors. Shares will start trading on a split-adjusted basis on September 9. The article also mentions other companies like Energy Resources of Australia, PainReform Ltd., BlackSky Technology, CapitaLand Integrated Commercial Trust, Cintas Corp., and BeijingWest Industries International Ltd., detailing their respective stock splits and financial activities.
Public Trading
growth-positive
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced the successful determination of the optimal delivery method for PRF-110 in bunionectomy procedures. This marks a significant milestone in advancing PRF-110 as a leading post-surgical pain management solution. The company has completed comprehensive Phase III evaluations, focusing on the practical application of the product in surgical wounds. The findings underscore PRF-110s exceptional physical properties, which ensure optimal coverage of cut nerve endings and traumatized tissue surfaces, contributing to effective post-surgical pain control.
CustomersInvestment
Growth-Positive
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced positive early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, a post-surgical pain formulation. The study, which has now completed full enrollment with a total of 443 patients across eight clinical sites in the United States, revealed a low incidence of adverse events. The companys CEO, Ehud Geller, stated that the results reinforce the potential of PRF-110 to be a game-changer in post-surgical pain management and a promising non-opioid alternative in the post-operative pain market.
Investment
growth-positive
PainReform Provides Business Update for the Second Quarter of 2024
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy and expects to announce top-line data in late 2024. The company has also developed a new highly scalable manufacturing process for PRF-110, which is expected to enhance future commercialization efforts. Financial results for the six months ended June 30, 2024, show an increase in research and development expenses and a decrease in general and administrative expenses. In April 2024, the company closed a public offering for gross proceeds of $4 million.
InvestmentManagement Changes
growth-positive
PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced the successful development and manufacturing of new patented formulations of its extended postoperative pain relief therapy, PRF-110. The new formulations may incorporate both the analgesic and an anti-inflammatory agent, designed to enhance postoperative recovery. The company holds a patent for the ropivacaine and dexamethasone mixture and has successfully manufactured specific combination products of PRF-110. PainReform remains committed to advancing its pipeline of innovative pain management therapies to improve patient outcomes and quality of life.
InvestmentExpand
growth-positive
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced positive safety data for its lead product candidate, PRF-110. The data, derived from pharmacokinetic studies in herniorrhaphy and bunionectomy clinical trials, shows PRF-110s promising safety profile. PRF-110 is a solution designed for direct application into the surgical wound bed before closure, providing localized and extended postoperative analgesia. The companys Chairman and interim CEO, Ehud Geller, stated that the safety data supports their belief in PRF-110s potential to enhance patient care in surgical settings.
InvestmentManagement Changes
growth-positive
PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced positive wound healing data from its human clinical trials investigating the efficacy of PRF-110, the companys lead asset designed to provide extended, non-opiate, post-surgical pain relief. The recent human clinical trials included patients undergoing both hard tissue and soft tissue surgeries. Results indicated no abnormalities in wound healing or scar formation among patients treated with PRF-110. The company is on track to report top-line results from the Phase 3 trial in the second half of 2024.
Investment
growth-positive
PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
PainReform Ltd. has announced a significant advancement in the development of its lead product, PRF-110. The companys new scalable manufacturing process has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This is a crucial milestone for PainReform as it simplifies logistics, reduces costs, and ensures safety and efficacy of the product. The company is confident that this new process will significantly bolster its future commercialization efforts. PainReform is on track to report top-line results from the Phase 3 trial in the second half of 2024.
Investment
growth-positive
PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has filed a patent for its new manufacturing process for PRF-110, its flagship product aimed at revolutionising post-operative pain control. The patent filing follows successful completion and testing of the new process. The improvements in the manufacturing process are expected to have a positive impact on the production cost of PRF-110, leading to a reduction in the cost of goods sold. The company has completed its bunionectomy Phase 3 trial and believes that PRF-110 has the potential to set a new standard in post-operative care.
Investment
growth-positive
PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate designed for the treatment of post-operative pain. The trial enrolled 428 patients across eight clinical sites in the U.S. The company anticipates reporting top-line results from the Phase 3 trial in the second half of 2024. The successful completion of enrollment marks a significant milestone in the development of PRF-110 and brings the company closer to potentially offering a new, non-opioid pain management solution to patients and healthcare providers.
Investment
growth-negative
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
PainReform Ltd has received a letter from the Nasdaq Listing Qualifications indicating that the company is not in compliance with the minimum bid price requirement for continued listing. The company has until November 25, 2024, to regain compliance with the minimum bid price requirement. If the company fails to demonstrate compliance by the end of the 180-day period, the Nasdaq’s staff will notify the company that its ordinary shares are subject to delisting. The companys lead product is PRF-110, an oil-based solution that provides localized and extended postoperative analgesia.
Public Trading
growth-positive
PainReform Provides Business Update for the First Quarter of 2024
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced that it has reached 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy. The company remains on track to announce top-line data in Q3 2024. The company also reported positive results from new studies, which demonstrated the superior in-vitro release rates of PRF-110 as compared to the industry leader for topical post-surgical pain management products. The companys Q1 2024 financial results showed an increase in research and development expenses and a decrease in general and administrative expenses.
Investment
growth-positive
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced that its CEO, Ilan Hadar, participated in an interview with Proactiveinvestors.com. During the interview, Hadar discussed the benefits of PRF-110 in addressing the opioid epidemic, including its ability to provide extended post-operative pain relief without the use of opioids. He also discussed the market potential for the product and gave positive updates on the companys ongoing Phase 3 clinical trial.
Management Changes
growth-positive
PainReform Announces Closing of $4 Million Public Offering
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has closed a public offering of 5 million ordinary shares and warrants to purchase up to 5 million ordinary shares at $0.80 per share. The gross proceeds from the offering, before deducting the placement agents fees and other offering expenses, were $4 million. The company intends to use the net proceeds from this offering to advance the company’s clinical studies and for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
InvestmentPublic Trading
growth-positive
PainReform Announces Pricing of $4 Million Public Offering
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced the pricing of a public offering of 5,000,000 of the Company’s ordinary shares and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of $0.80 per share. The gross proceeds from the offering, before deducting the placement agents fees and other offering expenses, are expected to be $4 million. The Company intends to use the net proceeds from this offering to advance the Company’s clinical studies, and for general corporate purposes.
InvestmentPublic Trading
growth-positive
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced positive results from new studies of its product, PRF-110. The studies demonstrated superior in-vitro release (IVR) rates of PRF-110 compared to the industry leader for topical post-surgical pain management products. The results support PRF-110s superior efficacy and its potential to significantly extend the duration of pain relief. The companys CEO, Ilan Hadar, expressed his enthusiasm about the findings, stating that they are a testament to the innovative approach the company is taking to combat post-surgical pain.
Investment
growth-positive
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
PainReform Ltd has announced results from new studies showing the superior in-vitro release (IVR) rates of its product PRF-110 compared to other post-surgical pain management products. The studies, which used the latest IVR technology, showed that PRF-110 released between 34%-77% more drug over 96 hours under various testing conditions. The results support PRF-110’s superior efficacy and its potential to extend the pain relief duration significantly. Last week, PainReform announced it reached the 50% enrollment target for the second part of the Phase 3 clinical trial of PRF-110 in bunionectomy.
Investment
growth-positive
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced that it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. Over 200 patients have been enrolled, with a target of approximately 400 patients at eight clinical sites across the U.S. The company is on track to announce top-line data by mid-2024. PainReforms CEO, Ilan Hadar, stated that there have been no reported serious adverse events, highlighting PRF-110’s potential safety.
Customers
growth-positive
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
PainReform Ltd has announced that it has reached the 50% enrollment target for the second part of the Phase 3 clinical trial of PRF-110 in bunionectomy. Over 200 patients have been enrolled, with a target of approximately 400 at eight clinical sites across the U.S. The companys CEO, Ilan Hadar, stated that there have been no reported serious adverse events, and they are on track to wrap up enrollment on schedule. PRF-110, the companys lead product, is based on the local anesthetic ropivacaine, which targets the postoperative pain relief market.
Customers
growth-positive
PainReform Provides Year-End Business Update
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has reported continued enrollment in the second part of its Phase 3 clinical trial for its lead drug candidate, PRF-110, an alternative to opioids for post-operative extended pain relief. The company has enrolled over 140 patients out of a target of 400 at six clinical sites across the U.S. It expects to announce top-line data by mid-2024. The companys financial results for the year ended December 31, 2023, show an increase in research and development expenses and a decrease in general and administrative expenses compared to the previous year.
Customers
growth-positive
PainReform to Present at the Microcap Conference in Atlantic City
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced that its management will be participating in The Microcap Conference held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino. Ilan Hadar, CEO of the Company, is scheduled to present at the conference and will also be participating in one-on-one meetings with qualified investors. The conference, organized by DealFlow Events, will feature company presentations from publicly traded microcap businesses and qualified private companies across various sectors.
Management Changes
growth-positive
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has reported positive in vitro test results for its lead product, PRF-110, a topical analgesia for postoperative pain relief. The tests showed that PRF-110 has superior formulation properties, including a greater ability to spread evenly and superior surface interaction with surgical tissue. The companys CEO, Ilan Hadar, expressed optimism about the products outlook as it advances in its Phase 3 clinical trial. Earlier, the company completed the first part of its Phase 3 clinical trial, which showed that PRF-110 was well tolerated and suggested a substantial potential advantage to using PRF-110 over opioids.
InvestmentExpand
Growth-Positive
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 467,896 ordinary shares at a reduced exercise price. The gross proceeds from the exercise of the warrants are expected to be approximately $1.3 million, which the company intends to use for funding research and development, clinical trials, and other working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 29, 2023.
Investment
Growth-Positive
PainReform Provides Business Update for the Third Quarter of 2023
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced the enrollment of the first patients for the second part of its Phase 3 clinical trial in bunionectomy. The trial is for PRF-110, the companys lead drug candidate, which targets the post-operative extended pain relief market. The trial will include up to 400 patients in the U.S., measuring pain reduction by PRF-110 over 72 hours compared with placebo and Naropin. Evolution Research Group (ERG) is serving as the contract research organization for the trial. The company also reported financial results for the nine months ended September 30, 2023, with a net loss of $4.5 million.
CustomersPartnersManagement Changes
growth-positive
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced plans to commence the second part of its phase 3 trial to evaluate PRF-110 in patients undergoing bunionectomy surgery. The trial is expected to proceed in the next quarter of 2023, following the clearance by FDA of the DMF held by the companys API manufacturer. The company reported positive safety data in the first part of the Phase 3 clinical trial with no serious adverse events reported. The second part of the trial will be a double-blind study, in which the company plans to randomize approximately 400 patients at seven clinical sites in the U.S.
InvestmentExpand
growth-positive
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has announced positive safety and pharmacokinetic data from the first part of its Phase 3 clinical trial of PRF-110 in patients undergoing bunionectomy surgery. The data will be presented at the 13th Congress of the European Pain Federation in September 2023. The trial enrolled 15 patients at two clinical sites in Texas, and PRF-110 was well tolerated with no serious adverse events observed. The second part of the trial will involve approximately 400 patients at seven clinical sites in the U.S.
InvestmentExpand
Growth-Positive
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced that its CEO, Ilan Hadar, will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York City from September 11-13, 2023. Hadar will be participating in one-on-one meetings with members of the investment community. PainReforms lead product is PRF-110, based on the local anesthetic ropivacaine, which targets the postoperative pain relief market. The product is designed to provide extended post-surgical pain relief without the need for repeated dose administration.
Investment
growth-positive
PainReform Provides Business Update for the Second Quarter of 2023
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced plans to commence the second part of its Phase 3 clinical trial in bunionectomy in Q4 2023. The companys lead drug candidate, PRF-110, is aimed at providing post-operative extended pain relief, reducing the potential need for opiates. The company has faced manufacturing issues, which resulted in a delay in the commencement of the second part of the Phase 3 trial. However, they have worked with their API supplier to resolve these issues. The company also reported financial results for the six months ended June 30, 2023, with a net loss of $4.5 million.
Management ChangesExpand
growth-positive
7 Stocks Under $10 to Buy for August
The article discusses seven companies with stocks priced under $10 that are considered good investment opportunities for August. These include Locafy, a search engine optimization specialist; Elys Game Technology, a tech gaming company; PainReform, a biotech company; ClearOne, a provider of professional-level audio and video products; Jupiter Wellness, a company that develops over-the-counter treatments; United Maritime, an international shipping company; and Superior Drilling Products, a company in the drilling tool technology business. The author notes that while these stocks can be volatile, they present good growth potential.
InvestmentCustomers
growth-positive
PainReform Regains Compliance with Nasdaq Continued Listing Requirements
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has regained compliance with the minimum bid price requirement under Nasdaq Rules 5550(a)(2). The companys CEO, Ilan Hadar, expressed satisfaction with the development, noting that it enhances the companys credibility and visibility. PainReform is currently advancing the second part of its Phase 3 trial evaluating the analgesic efficacy and safety of PRF-110 following surgery. The company believes PRF-110 could reduce the frequency of opiate use following surgical procedures.
Public Trading
growth-positive
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced a definitive agreement for the purchase and sale of 166,666 of the Company’s ordinary shares at a price of $9.00 per share in a registered direct offering. Concurrently, the company will issue unregistered warrants to purchase up to an aggregate of 166,666 ordinary shares. The offering is expected to close on July 18, 2023. The gross proceeds from the offerings are expected to be approximately $1.5 million, which will be used for funding research and development, clinical trials, and other working capital and general corporate purposes.
Investment
growth-positive
PainReform prices 301,230 shares at $9.00 in registered direct offering (NASDAQ:PRFX)
PainReform (NASDAQ:PRFX) has entered into a definitive agreement for the sale of 301,230 of its ordinary shares at $9 per share in a registered direct offering. Concurrently, the company will issue unregistered warrants to purchase up to an aggregate of 301,230 ordinary shares at $9 per share. These warrants will be exercisable immediately upon issuance and have a term of 5 years. The gross proceeds from the offerings are expected to be around $2.7M, which will be used for funding R&D, clinical trials, and other corporate purposes. The offering is expected to close on July 14, 2023.
Investment
growth-positive
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced a definitive agreement for the purchase and sale of 301,230 of the Company’s ordinary shares at a purchase price of $9.00 per ordinary share, in a registered direct offering. Concurrently, the Company will issue unregistered warrants to purchase up to an aggregate of 301,230 ordinary shares. The offering is expected to close on or about July 14, 2023. The gross proceeds from the offerings are expected to be approximately $2.7 million, which the Company intends to use for funding research and development and clinical trials and for other working capital and general corporate purposes.
Investment
growth-negative
PainReform (NASDAQ:PRFX) Tanks on $2.7M Registered Direct Offering - TipRanks.com
PainReform has announced a definitive agreement for the sale of 301,230 of its common shares at $9 each. Concurrently, the company has also announced a private placement of unregistered warrants for the purchase of nearly 301,230 common shares. The warrants can be exercised immediately after issuance and will have a period of five years and an exercise price of $9 per share. The company expects to raise $2.7 million in gross proceeds from the offerings and plans to use the funds for funding R&D activities, clinical trials, working capital and general corporate requirements.
Investment
growth-negative
Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely?
The article discusses the cash burn of PainReform and its potential impact on the company. PainReform, an early-stage business, has a cash runway of approximately 13 months as of March 2023. The companys cash burn has increased by 24% in the last year, indicating increased investment in the business. While PainReform has a solid cash runway, it may need to raise more cash for future growth. The companys cash burn is about 12% of its market capitalization, suggesting it wouldnt have much trouble raising more cash, but shareholders would be somewhat diluted. The article advises shareholders to monitor the companys cash burn over time. PainReform has 7 warning signs that investors should be aware of.
Investment
growth-positive
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
PainReform Ltd, a clinical-stage specialty pharmaceutical company, announced that its CEO, Ilan Hadar, will present at the Maxim Group Virtual Healthcare Conference, hosted by M-Vest, from June 20-22, 2023. The companys lead product, PRF-110, is an oil-based solution designed to provide localized and extended postoperative pain relief. The presentation will be webcast live on the M-Vest platform.
Management Changes
growth-negative
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
PainReform Ltd provided a regulatory update on the second part of its Phase 3 clinical trial of PRF-110. The Companys supplier of the API received a deficiency notice from the FDA, causing a delay in the trial. The deficiency notice is related to the manufacturing process and facility for the production of the API. The issues raised do not relate to the Companys PRF-110 product. PainReform is confident in the safety and quality of their product. PRF-110 aims to reduce opiate use following surgical procedures. The Company is working with the API supplier to resolve the deficiency notice and expects to commence the second part of the trial soon.
Partners
growth-positive
PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
PainReform Ltd. has reported positive pharmacokinetic data in the first part of its Phase 3 clinical trial for PRF-110, a reformulated therapeutic for postoperative pain relief. The trial enrolled 15 bunionectomy patients in Texas, and the results showed that PRF-110 had a favorable pharmacokinetic profile. The company plans to proceed to the second part of the trial, which will involve approximately 400 patients at seven clinical sites in the U.S. PRF-110 is an oil-based solution that provides localized and extended postoperative analgesia. PainReform is focused on the reformulation of established therapeutics and aims to reduce the need for repeated dose administration and the use of opioids.
CustomersInvestment
growth-positive
PainReform Provides Business Update for the First Quarter of 2023
PainReform Ltd. provided a business update on the progress of its Phase 3 clinical trial for PRF-110, a drug candidate for post-surgical pain relief. The company reported positive safety data and plans to transition to the larger part of the trial. PainReform aims to become the standard of care in the $12 billion post-operative pain relief market. In the first quarter of 2023, the company incurred a net loss of $2.3 million. PainReform had cash and cash equivalents of $8.1 million as of March 31, 2023.
Customers
PainReform CEO to Present at Aegis Virtual Conference on May 4th
growth-positive
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
PainReform Ltd. has reported positive safety results in the first part of its Phase 3 clinical trial for PRF-110, a reformulated therapeutic for postoperative pain relief. The trial enrolled 15 bunionectomy patients and demonstrated a solid safety profile with no serious adverse events reported. The company plans to proceed to the second part of the trial, which will be a double-blind study with approximately 400 patients. PRF-110 has the potential to become a standard-of-care treatment in the postoperative pain market. PainReform aims to address the significant unmet need for a long-acting local anesthetic agent to reduce opioid use. The companys CEO, Ilan Hadar, expressed optimism about the trials success and the potential of PRF-110.
Customers
growth-positive
PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th
PainReform Ltd., a clinical-stage specialty pharmaceutical company, announced that its CEO, Ilan Hadar, will be presenting at the Sequire Investor Summit in Puerto Rico. The summit, which will be held from April 24 – 26, 2023, will feature presentations from leading public companies, panel discussions, and interactive sessions addressing the latest trends in investor relations and technology. PainReform is focused on the reformulation of established therapeutics, with its lead product, PRF-110, currently in Phase III clinical trial for post-operative pain relief.
InvestmentManagement Changes
PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery
PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy
PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery
PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement
growth-positive
PainReform Provides Business Update for the Third Quarter of 2022
PainReform Ltd has implemented technology improvements related to the PRF-110 manufacturing process ahead of a planned Phase 3 clinical trial in bunionectomy. The company encountered a requirement for further work that delayed the start of the clinical trial but believes the issue is being rectified. PainReform ended the quarter with approximately $12.9 million cash and deposits on hand and no debt. The company plans to commence a second Phase 3 trial for pain treatment in hernia repair surgery. Financial results for the nine months ended September 30, 2022, showed an increase in research and development expenses and general and administrative expenses. The company incurred a net loss of $5.6 million for the period. PainReforms lead product, PRF-110, is an extended-release drug-delivery system designed to provide post-surgical pain relief without the need for repeated dose administration.
InvestmentExpand
Growth-Negative
PainReform Provides Further Update on Manufacturing of PRF-110
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has encountered issues in the manufacturing process of clinical batches for PRF-110, which will result in a delay in the commencement of their planned Phase 3 trial. The companys CEO, Ilan Hadar, stated that they are moving aggressively on their plans and expect to report further updates as it relates to the expected start of the clinical study as soon as practical. Despite the setback, the company remains optimistic about the outlook for the business based on the success of their prior Phase 2 proof-of-concept clinical study.
Management Changes
growth-negative
PainReform Provides Further Update on Manufacturing of PRF-110
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has announced issues in the manufacturing process of clinical batches for PRF-110, which will result in a delay in the commencement of their planned Phase 3 trial. The company has implemented enhancements to their manufacturing process for PRF-110 to improve efficiency and scalability. Despite the setback, the company remains optimistic about the business outlook based on the success of their prior Phase 2 proof-of-concept clinical study. If successful, PRF-110 has the potential to become standard-of-care within the $12 billion post-operative pain treatment market.
Management Changes
PainReform Provides PRF-110 Manufacturing Update
growth-positive
PainReform Provides PRF-110 Manufacturing Update
PainReform Ltd, a clinical-stage specialty pharmaceutical company, has completed a tech transfer to a contract manufacturing organization (CMO), resulting in new process improvements for its PRF-110 manufacturing process. The company expects these improvements to enhance efficiency and scalability. They have also added terminal filtration for PRF-110 to ensure high-quality batch production. PainReform remains on track to commence its Phase 3 clinical trial in bunionectomy in November 2022. PRF-110 is an extended-release drug-delivery system based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. The company aims to provide an extended period of post-surgical pain relief without the need for repeated dose administration and reduce the use of opiates.
InvestmentExpand
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
growth-negative
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
PainReform Ltd., a clinical-stage specialty pharmaceutical company, has received a letter from Nasdaq indicating that it is not in compliance with the minimum bid price requirement for continued listing. The company has until February 6, 2023, to regain compliance. If it fails to do so, its shares may be delisted. The companys shares will continue to trade on the Nasdaq Capital Market under the symbol PRFX during the grace period.
Public Trading
PainReform Provides Business Update for the Second Quarter of 2022
growth-positive
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th
PainReform Ltd. will present at the 2022 Virtual Growth Conference, showcasing a corporate update from the CEO. The company is focused on the reformulation of established therapeutics, with its lead product targeting the post-operative pain relief market. PainReforms proprietary extended-release drug-delivery system aims to provide extended pain relief without the need for repeated doses or opiates. The conference, presented by Maxim Group LLC and hosted by M-Vest, will feature roundtable discussions, fireside chats, and multiple company presentations. Attendees must sign up to become an M-Vest member to access the presentation.
PartnersInvestment
growth-negative
Do Analysts Agree Tuesday on PainReform Ltd (PRFX) Stock's Target Price?
PainReform Ltd (PRFX) has received an Analyst Rating Rank of 77, indicating that it is ranked higher by analysts than 77% of stocks. The average price target for PRFX is $10 and analysts rate the stock as a Hold. The stock is currently trading at $3.30, a drop of -$0.23 or -6.52% from the previous closing price. Volume today is lower than usual, with 44,165 shares traded compared to the average volume of 93,668 shares.
Public Trading
growth-negative
Is PainReform Ltd (PRFX) Stock About to Get Hot Friday?
PainReform Ltd (PRFX) stock has a bearish sentiment and has been down recently. The stock is lower by -8.43% while the S&P 500 has risen 0.17%. PRFX lost -$1.25 per share in the last 12 months. PainReform Ltd is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics.
Public Trading
growth-negative
Is PainReform Ltd (PRFX) Stock a Smart Investment Tuesday?
PainReform Ltd (PRFX) stock has experienced a significant decline since it began trading, and Wall Street analysts have given it a Strong Buy rating. The stock has a low overall score and a mean target price that suggests a potential increase in value. However, PRFX stock is currently lower while the S&P 500 is higher. The stock has been on a downward trend over the past year and has lost per share. The article provides information on the stocks performance and rankings.
Public Trading
growth-positive
PainReform Announces $6.0 Million Private Placement
PainReform Ltd. has entered into securities purchase agreements with certain institutional investors to raise approximately $6.0 million through a private placement. The funds will be raised by issuing 1,304,346 ordinary shares and accompanying warrants. The closing of the private placement is expected to occur on March 10, 2021. Maxim Group LLC is acting as the lead placement agent and Joseph Gunnar & Co., LLC is acting as co-placement agent for the transaction. The ordinary shares and warrants have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption. PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics.
Investment
growth-positive
PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference
PainReform Ltd. will be presenting at the H.C. Wainwright BioConnect 2021 Conference. The company is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Their lead product, PRF-110, is an extended-release drug-delivery system based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. The presentation will be available on-demand and accessible for 90 days.
Partners
growth-positive
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
PainReform Ltd has appointed Rita Keynan as Vice President of Pharmaceutical Operations. Keynan brings over 25 years of managerial experience in the pharmaceutical industry and has been responsible for drug development, manufacturing, and regulatory activities. The appointment is expected to support the companys Phase 3 pivotal trials for PRF-110, a reformulated therapeutic for post-operative pain relief. PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics.
Management Changes
growth-positive
PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors BioSpace
PainReform Ltd. welcomes Dr. Ellen Baron as a member of the Companys Board of Directors following its recent initial public offering. Dr. Baron brings extensive experience and a successful track record in both the healthcare industry and capital markets. Her expertise will be important as the company advances its planned Phase 3 trial, plans commercialization activities, and seeks out potential strategic partners. PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, with PRF-110 as its lead product targeting the post-operative pain relief market.
Management Changes
growth-positive
Israeli co PainReform raises $23m in Nasdaq IPO
Israel-based pharmaceutical company, PainReform, has raised $23 million in an Initial Public Offering (IPO) on Nasdaq at a company valuation of $70 million. The company, which specialises in pain therapeutics, held the IPO at $8 per share, at the lower end of the planned $8-$10 range. The share price lost 15% on its first day of trading. Maxim Group LLC and Joseph Gunnar & Co., LLC acted as joint book-runners for the offering.
InvestmentPublic Trading
IPO Preview: PainReform Begins $25 Million U.S. IPO Effort
growth-positive
PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study
PainReform Ltd, an Israel-based specialty pharmaceutical company, has received FDA approval to conduct two pivotal Phase III clinical trials for post-operative pain relief in soft and hard tissue. The trials will use PRF-110, a proprietary extended release version of ropivacaine (Naropin) which provides long relief of post-surgical incision pain. The company is currently raising $15 million to conduct the trials. The estimated market potential for pain relief drugs is $5 billion.
Investment
growth-positive
PainReform to conduct Phase III trials for pain reliever
Israeli drug development company Painreform is looking to raise $15 million to fund two Phase III trials of its pain reliever, which is designed for use in hospitals on patients recovering from surgery. The drug is based on delayed release over 72 hours. PainReform was founded in 2007 by Ofer Brothers venture capital fund, now known as XT Holdings, which no longer invests in young companies; private equity fund Viola; and Medica Venture Partners. The company is considering an IPO on Nasdaq.
Investment
News
PainReform Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 7 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
PainReform Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 514056597 |
| Crunchbase | painreform |
| Phone | +97237177051 |
| Creator | Rachel Wain |
| Creator email | rachelwain18@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-01T00:00:00.000Z |
| Created | 2014-11-30T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Sep, 2020; |